|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
EP4436571A4
(en)
*
|
2021-11-24 |
2025-10-15 |
Merck Sharp & Dohme Llc |
SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
CA3247639A1
(en)
|
2022-05-06 |
2023-11-09 |
PAQ Therapeutics Inc. |
CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
|
|
WO2023213269A1
(en)
*
|
2022-05-06 |
2023-11-09 |
Zai Lab (Shanghai) Co., Ltd. |
Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
|
|
CR20240508A
(es)
|
2022-05-19 |
2024-12-20 |
Genentech Inc |
Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
EP4540244A1
(en)
*
|
2022-06-15 |
2025-04-23 |
Mirati Therapeutics, Inc. |
Prodrugs of pan-kras inhibitors
|
|
EP4549439A1
(en)
*
|
2022-07-01 |
2025-05-07 |
Suzhou Zelgen Biopharmaceutical Co., Ltd. |
Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof
|
|
WO2024008068A1
(en)
*
|
2022-07-04 |
2024-01-11 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
WO2024012519A1
(zh)
*
|
2022-07-13 |
2024-01-18 |
北京华森英诺生物科技有限公司 |
Pan-kras抑制剂
|
|
WO2024041606A1
(zh)
*
|
2022-08-24 |
2024-02-29 |
泰励生物科技（上海）有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
TW202430179A
(zh)
|
2022-11-21 |
2024-08-01 |
美商樹線生物科學公司 |
螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025038936A1
(en)
|
2023-08-17 |
2025-02-20 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
CN121941690A
(zh)
|
2023-10-03 |
2026-04-28 |
Paq医疗公司 |
Kras蛋白水解靶向嵌合体
|
|
TW202529804A
(zh)
|
2023-10-06 |
2025-08-01 |
美商安進公司 |
用於癌症治療的組合療法
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
US20250114339A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202602882A
(zh)
*
|
2024-03-14 |
2026-01-16 |
美商安進公司 |
作為ｋｒａｓ調節劑的大環化合物及其用途
|
|
WO2025194054A1
(en)
*
|
2024-03-14 |
2025-09-18 |
Amgen Inc. |
Spirocyclic compounds as modulators of kras and uses thereof
|
|
WO2025228384A1
(en)
*
|
2024-04-30 |
2025-11-06 |
Hutchmed Limited |
Antibody-drug conjugates and use thereof
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|